Great talk by Chiara Favaretto at #ISRS23 on to the clinical translation of a terbium-161 labeled somatostatin antagonist for an ongoing study at the University Hospital Basel.

Congratulations to Cristina Müller on her promotion to titular professor at D-CHAB by the ETH-Rat (ethrat.ch/en/appointment…). Well deserved!

🎙️ New podcast episode is out! Hear, hear and learn (so much!) about new #PSMA–binding ligands with #161Tb from the wonderful Jason Lewis Radiochem MSK around a paper by the team of Cristina Müller... & along your way just never forget to “smell the roses 🌹” e-smi.eu/podcast/

I am pleased with our recent publication on radiolabeled exendin-4 with cleavable linkers that significantly reduce renal uptake. I congratulate my former PhD students Belinda Trachsel and Giulia Valpreda for their excellent contributions. #radiopeptide rdcu.be/dld9u

Terbium-161 developed at the Paul Scherrer Institute PSI Paul Scherrer Institut hits the clinic | Labs & User Services | Paul Scherrer Institut (PSI) psi.ch/en/science/sci…

(🧵3/5) Colleagues Daniela Kiselev, Klaus Kirch and Roger Schibli Roger Schibli presented the #IMPACT project, a major upgrade of the proton accelerator planned for the coming years. Forward-looking research requires constantly updated facilities!

Excited to share our latest paper in Scientific Reports Scientific Reports on Terbium-149 production, emphasizing advancements in yield and quality for preclinical applications doi.org/10.1038/s41598….

Thirty amazing and happy radiopharmacists from all over the world successfully finished the ETH Zurich #ETH_en module of the Certificate of Advanced Studies in Radiopharmaceutical Chemistry/Radiopharmacy radiochem.pharma.ethz.ch! Thank you to everyone who contributed!

Joint efforts by #ETH_en, #psich_en, #schibli_CRS and #KSB_Spitalbaden bring us one step closer to understanding and potentially imaging endometriosis in the future; check out the latest publication: rdcu.be/dyOdG

🎉#HappyBirthdayHIPA. Last Tuesday, we celebrated 50 years of #HIPA with Michael Hengartner, President ETH-Rat, our director Christian Rüegg and scientists, engineers, and technicians who have worked on HIPA and are working here at PSI Paul Scherrer Institut 🙏 #HIPA #IMPACT #ResearchAtPSI

Our first-in-human administration of a terbium-161-labelled somatostatin receptor antagonist just got published rdcu.be/dAzbR! The crowning success of our pioneering work on terbium-161 starting 12 years ago sciencedirect.com/science/articl….

Dr. Katherina Mapanao and Rahel Wallimann presenting our latest results on alpha-particle therapy with 149Tb-labeled somatostatin analogs and laser-ablation ICO-MS experiments with “cold” lutetium-labeled PSMA and folate at #EMIM2024!

After COVID is before COVID: Read our latest pre-print on the "Development of radiofluorinated MLN-4760 derivatives for PET imaging of the SARS-CoV-2 entry receptor ACE2" biorxiv.org/content/10.110…

#ICYMI we presented data at the AACR Annual Meeting 2024 on two novel dual TOP1i ADCs targeting HER2 and NaPi2b that showed high stability and high anti-tumor activity in mouse models. Read more here: bit.ly/3Kp6tBq

Take a look at our article on the tolerability of 161Tb vs 177Lu: link.springer.com/10.1007/s00259…

The Institute of Pharmaceutical Sciences at the ETH Zurich is looking for an Assistant Professor (tenure track) for Biopharmaceutical Systems and Pharmacokinetics. Interested candidates are invited to apply online via the link below. ethz.ch/en/the-eth-zur…

Scientists led by Jörg Scheuermann found a way to produce / test DNA-encoded #chemicallibraries, using #magneticparticles. This technology can be used to find new active pharmaceutical ingredients. Check out the article 👇 doi.org/10.1126/scienc… ethz.ch/en/news-and-ev…

Just published! First-in-human data on [161Tb]Tb-SibuDAB, a novel radioligand designed for enhanced radioligand therapy in metastatic castrate-refractory prostate cancer (doi.org/10.1007/s00259…). A successful collaboration between @PSI, UniSpitalBaselCH, ETH Zürich and Göteborgs universitet / University of Gothenburg.

We are very excited to announce a major research collaboration and option to license agreement with Chugai Pharmaceutical! ararisbiotech.com/docs/250106_25… #Araris #ADCs